GlassScriptPhysician profile
Robert Jalosinski
NPI 1538385299
$8,907.11
in general payments reported to CMS, 2019-2025
13 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $729 · 2021: $1,182 · 2022: $1,017 · 2023: $1,934 · 2024: $1,513 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,276.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.75 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,437.22 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,432.75 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $1,404.47 | 2019-2025 | Dyanavel Xr, Quillichew Er, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $768.29 | 2020-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $470.06 | 2019-2024 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $438.34 | 2024-2025 | Auvelity |
| Adlon Therapeutics L.P. | $356.05 | 2020-2021 | |
| Allergan, INC. | $240.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $222.48 | 2019 | |
| Lundbeck LLC | $189.29 | 2023-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $134.48 | 2019-2021 | |
| Shire North American Group INC | $25.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jalosinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.